



FOR IMMEDIATE RELEASE

TSX Venture Exchange: FYT

FYTOKEM ANNOUNCES PRODUCT SAFETY TESTS

Saskatoon, Saskatchewan, March 1, 2005 - Fytokem Products Inc. (Fytokem), a leading producer of *Function-Certified™* plant-based ingredients, today announced that it has completed a detailed set of studies again confirming the safety of its primary product Canadian Willowherb™.

A series of toxicity trials, including Reverse Mutation Analysis, Skin Irritation, Photoallergy, Photoirritation and Skin Sensitization tests have been completed at the Indian Institute of Toxicology. This Institute, located in Pune, India, is well recognized as an independent third party providing accurate toxicology analysis for the cosmetic and pharmaceutical industries. This series of tests was conducted to confirm and expand on earlier work and provide current information demonstrating the safety of Canadian Willowherb™. Each of the tests produced negative results, confirming the opportunity for Canadian Willowherb as an active ingredient in topical skin products.

“The results obtained are exactly what we expected. Canadian Willowherb™ has repeatedly demonstrated it is a safe and effective multi-function cosmetic ingredient. These recent studies will allow us to meet the growing demand for this line of active ingredients in new and different markets,” said Art Hesje, President and CEO of Fytokem. “As consumers demand higher quality for all natural products, it is encouraging that we are able to both demonstrate strong efficacy and meet rising standards for safety. I’m also pleased to see that we can demonstrate this safety under very different conditions.”

About Fytokem Products Inc.

Fytokem Products Inc. is engaged in the discovery and commercialization of novel *Function-Certified™* plant-based substances – extracts, phytochemicals and bioactive molecules – for use as ingredients in personal care, nutraceutical, pharmaceutical and bio-industrial products. The Company has been issued patents for technology related to two of its products and has other patent applications pending.

The TSX Venture Exchange has neither approved nor disapproved the information herein contained.

-30-

For more information, please contact

Art Hesje, President and CEO

Fytokem Products Inc.

306-668-2552 tel, 306-978-2436 fax

ahesje@fytokem.com

www.fytokem.com